347 related articles for article (PubMed ID: 21810596)
1. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.
Himeno T; Kamiya H; Naruse K; Harada N; Ozaki N; Seino Y; Shibata T; Kondo M; Kato J; Okawa T; Fukami A; Hamada Y; Inagaki N; Seino Y; Drucker DJ; Oiso Y; Nakamura J
Diabetes; 2011 Sep; 60(9):2397-406. PubMed ID: 21810596
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.
Jolivalt CG; Fineman M; Deacon CF; Carr RD; Calcutt NA
Diabetes Obes Metab; 2011 Nov; 13(11):990-1000. PubMed ID: 21635674
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
Liu WJ; Jin HY; Lee KA; Xie SH; Baek HS; Park TS
Br J Pharmacol; 2011 Nov; 164(5):1410-20. PubMed ID: 21323903
[TBL] [Abstract][Full Text] [Related]
4. Magnolol effectively ameliorates diabetic peripheral neuropathy in mice.
Yang J; Wei Y; Zhao T; Li X; Zhao X; Ouyang X; Zhou L; Zhan X; Qian M; Wang J; Shen X
Phytomedicine; 2022 Dec; 107():154434. PubMed ID: 36122436
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.
Kan M; Guo G; Singh B; Singh V; Zochodne DW
J Neuropathol Exp Neurol; 2012 Jun; 71(6):494-510. PubMed ID: 22588388
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro.
Takaku S; Tsukamoto M; Niimi N; Yako H; Sango K
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804063
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice.
Urban MJ; Li C; Yu C; Lu Y; Krise JM; McIntosh MP; Rajewski RA; Blagg BS; Dobrowsky RT
ASN Neuro; 2010 Aug; 2(4):e00040. PubMed ID: 20711301
[TBL] [Abstract][Full Text] [Related]
8. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult.
Mohiuddin MS; Himeno T; Inoue R; Miura-Yura E; Yamada Y; Nakai-Shimoda H; Asano S; Kato M; Motegi M; Kondo M; Seino Y; Tsunekawa S; Kato Y; Suzuki A; Naruse K; Kato K; Nakamura J; Kamiya H
J Diabetes Res; 2019; 2019():9426014. PubMed ID: 30918901
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
Kodera R; Shikata K; Kataoka HU; Takatsuka T; Miyamoto S; Sasaki M; Kajitani N; Nishishita S; Sarai K; Hirota D; Sato C; Ogawa D; Makino H
Diabetologia; 2011 Apr; 54(4):965-78. PubMed ID: 21253697
[TBL] [Abstract][Full Text] [Related]
11. Protection of exendin-4 analogue in early experimental diabetic retinopathy.
Zhang Y; Wang Q; Zhang J; Lei X; Xu GT; Ye W
Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):699-706. PubMed ID: 19084986
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury.
Yamamoto K; Amako M; Yamamoto Y; Tsuchihara T; Nukada H; Yoshihara Y; Arino H; Fujita M; Uenoyama M; Tachibana S; Nemoto K
Biomed Res Int; 2013; 2013():315848. PubMed ID: 23984340
[TBL] [Abstract][Full Text] [Related]
14. Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
Barakat G; Moustafa ME; Khalifeh I; Hodroj MH; Bikhazi A; Rizk S
J Physiol Biochem; 2016 Aug; 73(3):387-394. PubMed ID: 28589533
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 modulates diabetes onset in nonobese diabetic mice.
Hadjiyanni I; Baggio LL; Poussier P; Drucker DJ
Endocrinology; 2008 Mar; 149(3):1338-49. PubMed ID: 18063685
[TBL] [Abstract][Full Text] [Related]
16. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan JN; Cheng HN; Young CC; Lee CJ; Yeh ML; Luo CY; Tsai YS; Lam CF
J Surg Res; 2017 Feb; 208():93-103. PubMed ID: 27993221
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
20. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
